FDA Approves New Treatment for Advanced Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) approved a new treatment for advanced pancreatic cancer on August 26, 2026. The drug, daraxonrasib, will be marketed under the brand name Rasonque and is intended for patients with metastatic pancreatic adenocarcinoma, the most common type of pancreatic cancer. Developed by Revolution Medicines, Rasonque is a once-daily pill that targets RAS proteins involved in tumor growth. The approval is for adults who have already received at least one cancer treatment or who cannot undergo combination treatment. This decision came approximately 6.5 months ahead of the FDA's target date following an expedited review process. Acting FDA Commissioner Kyle Diamantas stated that this approval provides a critical new option for patients with a difficult-to-treat cancer. The approval was based on a clinical trial involving 500 patients whose cancer had progressed after previous treatments. Results showed that patients taking daraxonrasib had a median overall survival of 13.2 months, compared to 6.7 months for those receiving standard chemotherapy. Additionally, the drug significantly delayed disease progression, with patients going about twice as long without their cancer worsening. The risk of death was reduced by 60% in the trial. Experts, including Andrew Ko from the University of California, noted the potential transformative impact of this treatment on pancreatic cancer care. The National Cancer Institute estimates that 67,530 Americans will be diagnosed with pancreatic cancer in 2026, with 52,740 expected to die from the disease. The overall five-year relative survival rate for pancreatic cancer is 13.3%. Common side effects of Rasonque include rash, diarrhea, mouth inflammation, nausea, fatigue, vomiting, abdominal pain, swelling, decreased appetite, and hemorrhage.